Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity-Reference-Cited by-同舟云学术

Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity

Published:2019-07-17 Issue:501 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Marshall Emily E.¹^ORCID,Malouli Daniel¹^ORCID,Hansen Scott G.¹^ORCID,Gilbride Roxanne M.¹,Hughes Colette M.¹,Ventura Abigail B.¹,Ainslie Emily¹^ORCID,Selseth Andrea N.¹,Ford Julia C.¹^ORCID,Burke David¹,Kreklywich Craig N.¹,Womack Jennie¹^ORCID,Legasse Alfred W.¹^ORCID,Axthelm Michael K.¹^ORCID,Kahl Christoph¹^ORCID,Streblow Daniel¹,Edlefsen Paul T.²^ORCID,Picker Louis J.¹^ORCID,Früh Klaus¹^ORCID

Affiliation:

1. Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

2. Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Abstract

Live-attenuated, spread-deficient rhesus CMV vectors retain T cell immunogenicity.

Funder

NIH Office of the Director

National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference81 articles.

1. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection